SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K
                                 CURRENT REPORT



     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



        Date of Report (Date of earliest event reported) November 9, 2004



                         Progenics Pharmaceuticals, Inc.
             (Exact name of registrant as specified in its charter)



           Delaware                   000-23143              13-3379479
 (State or other jurisdiction         (Commission           (IRS Employer
      of incorporation)               File Number)         Identification No.)



             777 Old Saw Mill River Road, Tarrytown, New York 10591
               (Address of principal executive offices) (Zip Code)


        Registrant's telephone number, including area code (914) 789-2800


     Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

|_|  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

|_|  Pre-commencement communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

|_|  Pre-commencement   communications  pursuant  to  Rule  13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))





Section 2 - Financial Information

         Item 2.02.        Results of Operations and Financial Condition

     On  November  9,  2004,  Progenics  Pharmaceuticals,   Inc.  announced  its
operational  results  for the  third  quarter  and  first  nine  months of 2004.
Progenics  Pharmaceuticals also updated the status of its ongoing clinical trial
studies,  reporting progress in its efforts to bring its developmental  drugs to
market. A copy of the press release is attached as Exhibit 99.1.

     The information  furnished pursuant to Item 2.02 in this Form 8-K shall not
be deemed  to be  "filed"  for the  purposes  of  Section  18 of the  Securities
Exchange Act of 1934 or otherwise  subject to the  liabilities  of that Section,
unless we specifically incorporate it by reference in a document filed under the
Securities Act of 1933 or the  Securities  Exchange Act of 1934. We undertake no
duty or  obligation  to  publicly  update or revise  the  information  furnished
pursuant to Item 2.02 in this Form 8-K.

Section 9 - Financial Statements and Exhibits

         Item 9.01    Financial Statements and Exhibits

                      (c) the following exhibit is furnished with this report

                      Exhibit Number                Description
                      99.1                          Press Release dated 
                                                    November 9, 2004





                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                            PROGENICS PHARMACEUTICALS, INC.


                                           By:  /s/ ROBERT A. MCKINNEY      
                                                    Robert A. McKinney
                                                    Vice President, Finance and 
                                                    Operations


Date:  November 9, 2004